^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Esophageal Cancer

    Related cancers:
    10h
    BEMAFLOT: Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b (clinicaltrials.gov)
    P2, N=0, Withdrawn, Institut Cancerologie de l'Ouest | N=49 --> 0 | Trial completion date: Jun 2034 --> Jan 2026 | Not yet recruiting --> Withdrawn | Trial primary completion date: Jun 2029 --> Jan 2026
    Enrollment change • Trial completion date • Trial withdrawal • Trial primary completion date
    |
    FGFR2 overexpression
    |
    docetaxel • oxaliplatin • bemarituzumab (AMG 552)
    14h
    (BLOOM): Lactulose to Improve Gut Health in Cancer Patients Receiving Immunotherapy (clinicaltrials.gov)
    P1/2, N=55, Not yet recruiting, University of Chicago
    New P1/2 trial
    |
    TMB (Tumor Mutational Burden)
    |
    TMB-H
    15h
    Neoadjuvant Treatment Modalities in Esophageal Cancer (clinicaltrials.gov)
    P3, N=2000, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Dec 2025 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2030
    Trial completion date • Trial primary completion date
    |
    paclitaxel • 5-fluorouracil • TheraCIM (nimotuzumab)
    16h
    Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer (clinicaltrials.gov)
    P3, N=2000, Recruiting, Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Trial completion date: Dec 2025 --> Dec 2030 | Trial primary completion date: Dec 2025 --> Dec 2030
    Trial completion date • Trial primary completion date
    |
    paclitaxel • 5-fluorouracil • TheraCIM (nimotuzumab)
    19h
    A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (clinicaltrials.gov)
    P3, N=555, Recruiting, RemeGen Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 overexpression • HER-2 expression
    |
    Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Tevimbra (tislelizumab-jsgr) • capecitabine • oxaliplatin • Aidixi (disitamab vedotin)
    1d
    Mendelian randomization study of the role of TD CD4+ T cells in the association between Streptococcus thermophilus and esophageal cancer. (PubMed, Medicine (Baltimore))
    This study identifies Streptococcus thermophilus as a potentially protective gut commensal that may reduce EC risk through immune modulation. The findings provide novel insights into microbiome-immune-cancer interactions and suggest possible preventive or therapeutic targets for EC.
    Journal
    |
    CD4 (CD4 Molecule)
    1d
    PKU-ESCC-EF: Standardized Management of Esophageal Fistula in Esophageal Squamous Cell Carcinoma (clinicaltrials.gov)
    P=N/A, N=32, Not yet recruiting, Peking University Cancer Hospital & Institute
    New trial
    1d
    Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC (clinicaltrials.gov)
    P3, N=550, Recruiting, Jiangsu HengRui Medicine Co., Ltd. | Trial completion date: Sep 2022 --> Sep 2026 | Trial primary completion date: Apr 2022 --> Apr 2026
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    paclitaxel • AiRuiKa (camrelizumab) • AiTan (rivoceranib) • irinotecan
    1d
    CAMPERR: cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease (clinicaltrials.gov)
    P=N/A, N=7000, Recruiting, Adela, Inc | Trial completion date: Dec 2026 --> Mar 2027 | Trial primary completion date: Sep 2025 --> Mar 2026
    Trial completion date • Trial primary completion date • Minimal residual disease
    2d
    FREEDOM: Flexi Band Resistance Training Versus EMS Exercise in Patients With the Diagnosis of Malignant Diseases (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, University of Erlangen-Nürnberg Medical School | Unknown status --> Recruiting | Trial completion date: Mar 2022 --> Jun 2026 | Trial primary completion date: Mar 2022 --> Jun 2026
    Enrollment open • Trial completion date • Trial primary completion date
    2d
    Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Select Advanced Solid Tumor Indications Receiving Intravenous (IV) ABBV-400 (clinicaltrials.gov)
    P1, N=302, Active, not recruiting, AbbVie | Recruiting --> Active, not recruiting
    Enrollment closed • Adverse events
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    telisotuzumab adizutecan (ABBV-400) • itraconazole
    2d
    The mutual regulation of SOX12 and RNF168 modulates cisplatin resistance in esophageal squamous cell carcinoma cells by regulating DNA damage repair. (PubMed, Cell Biosci)
    Collectively, our study identifies a feedback regulatory loop between SOX12 and RNF168 that promotes DNA damage repair and cisplatin resistance in esophageal cancer cells.
    Journal
    |
    SOX2 • TRIP12 (Thyroid Hormone Receptor Interactor 12) • UBR5 (Ubiquitin Protein Ligase E3 Component N-Recognin 5) • RNF168 (Ring Finger Protein 168)
    |
    cisplatin